Recombinant Human Tumor necrosis factor receptor superfamily member 10B(TNFRSF10B),Partial (Active)

In Stock
Code CSB-AP002291HU
Size US$1637Purchase it in Cusabio online store
(only available for customers from the US)
Image
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity >97% as determined by SDS-PAGE and HPLC.
Endotoxin Less than 1.0 EU/μg as determined by LAL method.
Activity Fully biologically active when compared to standard. rHusTRAIL-R2 reduced the production of LPS- induced TNF by its ability to neutralize endogenous TRAIL in fresh human PBMC. In this assay, endogenous TRAIL is induced during a 24 hour exposure to LPS (10 ng/mL) but in the presence of rHusTRAIL-R2, TRAIL-induced TNF is suppressed.
Target Names TNFRSF10B
Uniprot No. O14763
Research Area Cancer
Alternative Names as like protein; Apoptosis inducing protein TRICK2A/2B; Apoptosis inducing receptor TRAIL R2; CD262; CD262 antigen; Cytotoxic TRAIL receptor 2; Death domain containing receptor for TRAIL/Apo 2L; Death receptor 5; DR5; KILLER; KILLER/DR5; OTTHUMP00000123492; OTTHUMP00000123493; p53 regulated DNA damage inducible cell death receptor(killer); TNF related apoptosis inducing ligand receptor 2; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TR10B_HUMAN; TRAIL R2; TRAIL receptor 2; TRAIL-R2; TRAILR2; TRICK2; TRICK2A; TRICK2B; TRICKB; Tumor necrosis factor receptor like protein ZTNFR9; Tumor necrosis factor receptor superfamily member 10B; Tumor necrosis factor receptor superfamily; member 10b; ZTNFR9
Species Homo sapiens (Human)
Source E.Coli
Expression Region 52-183aa
Complete Sequence ESALITQQDL APQQRAAPQQ KRSSPSEGLC PPGHHISEDG RDCISCKYGQ DYSTHWNDLL FCLRCTRCDS GEVELSPCTT TRNTVCQCEE GTFREEDSPE MCRKCRTGCP RGMVKVGDCT PWSDIECVHK ES
Mol. Weight 14.8 kDa
Protein Length Partial
Tag Info Tag-Free
Form Liquid or Lyophilized powder
Buffer 0.2um filtered PBS, pH 7.4 ,lyophilized
Troubleshooting
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.
Datasheet & COA Please contact us to get it.

Target Data

Function Receptor for the cytotoxic ligand TNFSF10/TRAIL
Gene References into Functions
  1. in vivo data confirmed that anti-tumor activity of bigelovin in Colorectal cancer (CRC)was through induction of apoptosis by up-regulating DR5 and increasing ROS. In conclusion, these results strongly suggested that bigelovin has potential to be developed as therapeutic agent for CRC patients PMID: 28181527
  2. GDF-15 and TRAIL-R2 were the most powerful Proximity Extension Assay chip biomarkers in predicting long-term all-cause mortality in patients with acute myocardial infarction. PMID: 28762762
  3. In contrast to apoptosis, necroptotic signaling was activated similarly by both DR4- or DR5-specific ligands..Our study provides the first systematic insight into DR4-/DR5-specific signaling in colorectal and pancreatic cancer cells PMID: 29278689
  4. These data suggest that the humanized anti-TRAIL-R2 monoclonal antibody or the second generation of the antibody may have an important clinical usage for cancer immunotherapy PMID: 28748573
  5. We found that pharmacological application of Golgi stress leads to induction of death receptors (DRs) 4 and 5. DR4 appears to be primarily responsible for the initiation of cell death downstream of Golgi stress, whereas DR5 seems to be more important for cell death triggered by endoplasmic reticulum (ER) stress in specific cancer cell lines PMID: 28981087
  6. Knocking-down of TRAIL-DR5 gene in breast cancer cells MCF-7 markedly decreased the mRNA and protein levels of the autophagy-related factors. PMID: 29268854
  7. Antineoplasic agents etoposide (ET) and doxorubicin enhance the expression of Death receptor 5 (DR5) in triple-negative breast cancer (TNBC) cells. DR5 residue SerB68 is important in mediating the receptor-drug interaction. Apoptosis and DR5 expression are induced in xenograft mice and in TNBC patient-derived metastatic cells after treatment with TNF-Related Apoptosis-Inducing Ligand (TRAIL) and ET. PMID: 28702823
  8. DR5, BIRC5/Survivin, XIAP, c-IAP1 and c-IAP2 mRNA expression are significantly deregulated in CRC and could provide a panel of markers with significant discriminatory value between CRC and normal colorectal tissue PMID: 27827395
  9. The B-Raf inhibitor PLX4032 induces DR5 upregulation exclusively in Ras-mutant cancer cells; this effect is dependent on Ras/c-Raf/MEK/ERK signaling activation. PMID: 27222248
  10. EPHB6 induces marked fragmentation of the mitochondrial network in breast cancer cells of triple-negative origin. This response renders cancer cells more susceptible to DR5-mediated apoptosis. PMID: 27788485
  11. Both S1P and caspase-8 are critical for TRAF2 stabilization, polyubiquitination, subsequent activation of JNK/AP1 signaling and MMP1 expression and final promotion of cell invasion. PMID: 28482915
  12. DNA fragmentation, mitochondrial membrane potential and western blot analyses showed that MIC inhibited the growth of these cells by both mitochondrialmediated and death receptor (DR5)mediated apoptosis pathways PMID: 28498480
  13. targeting of lysosomes by chloroquine deregulates DR5 trafficking and abrogates 5-FU- but not TRAIL-stimulated cell elimination, hence suggesting a novel mechanism for receptor activation PMID: 27506940
  14. siRNA silencing of CHOP significantly reduced cyproterone acetate-induced DR5 up-regulation and TRAIL sensitivity in prostate cancer cells. Our study shows a novel effect of cyproterone acetate on apoptosis pathways in prostate cancer cells and raises the possibility that a combination of TRAIL with cyproterone acetate could be a promising strategy for treating castration-resistant prostate cancer PMID: 28270124
  15. PU.1 supports TRAIL-induced cell death by inhibiting RelA-mediated cell survival and inducing DR5 expression. PMID: 28362429
  16. The results demonstrated CaM binding to DR5-mediated DISC in a calcium dependent manner and may identify CaM as a key regulator of DR5-mediated DISC formation for apoptosis in breast cancer. PMID: 28092099
  17. The oncogene-like extracellular miR-1246 could act as a signaling messenger between irradiated and non-irradiated lung cancer cells, more importantly, it contributes to cell radioresistance by directly suppressing the DR5 gene. PMID: 27129166
  18. Data show that 4EGI-1 compound induced apoptosis in nasopharyngeal carcinoma cells through the death receptor 5 (DR5) on 4E-BP1 dephosphorylation exerting positive influence on their anti-tumor activities. PMID: 26942880
  19. Results show that downregulation of DR4 and DR5 by SLC26A2 confers resistance to TRAIL. PMID: 28108622
  20. Study provides direct biophysical evidence that Death Receptor 5 disulfide-linked transmembrane (TM)-dimers open in response to ligand binding. Then, to probe the importance of the closed-to-open TM domain transition in the overall energetics of receptor activation, point-mutants (alanine to phenylalanine) in the predicted, tightly packed TM domain dimer interface were designed and tested. PMID: 28746849
  21. Oridonin analog CYD-6-28 induces apoptosis at least partially by inducing the expression of death receptor 5 in breast neoplasms. PMID: 27387452
  22. The authors show that cholesterol is necessary for the covalent dimerization of DR5 transmembrane domains. PMID: 27720987
  23. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. PMID: 28459212
  24. MG132 possesses anti-gallbladder cancer potential that correlate with regulation of DR5-dependent pathway. PMID: 27277541
  25. CAPE/TRAIL stimulated apoptosis through the binding of TRAIL to DR5. Moreover, expression of transcription factor C/EBP homologous protein (CHOP) markedly increased in response to CAPE and transient knockdown of CHOP abolished CAPE/TRAIL-mediated apoptosis. PMID: 27260301
  26. Decreased level of placental TRAIl-R2 and previous C-section were found to be significantly correlated to placenta accreta. PMID: 26992667
  27. Results show that calmodulin (CaM) directly binds to death receptor-5 (DR5) in a calcium dependent manner in breast cancer cells. PMID: 27129269
  28. Bee venom inhibits colon cancer cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 and DR5 and inhibition of NF-kappaB activity. PMID: 26561202
  29. study involving a relatively large sample size showed that TNFRSF10 eQTL SNPs within lncRNAs might influence both hepatocellular carcinoma development and HBV infection PMID: 26297860
  30. Data show that when death receptor 5 (DR5) is suppressed, caspase-8 may recruit and stabilize TNF receptor-associated factor 2 (TRAF2) to form a metastasis and invasion signaling complex, resulting in activation of ERK signaling. PMID: 26510914
  31. Synthetic lipid bilayers displaying the membrane protein ligand Apo2L/TRAIL were used to stimulate death receptor-expressing cells in a modular, scalable format PMID: 26458551
  32. Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression PMID: 25724522
  33. Studied an array of TRAIL-R1 and TRAIL-R2 specific variants on pancreatic cancer cells. PMID: 26138346
  34. The expression of two proapoptotic genes, FAS and DR5, was significantly lower in tumor samples than in adjacent normal tissues PMID: 25795228
  35. In an osteotropic variant of MDA-MB-231 breast cancer cells, TRAIL-R2 knockdown leads to downregulation of HMGA2, p-Src, p-Akt and CXCR4 and increased E-cadherin expression. These changes diminished occurrence of skeletal metastases in vivo. PMID: 25909161
  36. mutant genotype (CT+TT) of DR5 (rs1047266) may exert a negative synergistic effect on crohn disease. PMID: 26418999
  37. Studied the apoptosis of hepatic stellate cells induced by SEA; found it could be reduced in hepatic stellate cells that were treated with p53-specific siRNA and in hepatic stellate cells that were treated with DR5-specific shRNA. PMID: 25144704
  38. Taken together, our results strongly suggest that FLLL12 induces apoptosis of lung cancer cell lines by posttranscriptional regulation of DR5 through activation of protein tyrosine phosphatase(s). PMID: 25917567
  39. findings highlight novel mechanisms underlying endoplasmic reticulum stress-induced TNFRSF10A and TNFRSF10B expressions and apoptosis. PMID: 25770212
  40. DR5 expression is dramatically reduced as a function of higher prostate tumor grade. PMID: 25174820
  41. was statistically significant association between DR5 expression and tumor site of asal cell and squamous cell carcinoma skin cancers PMID: 24212133
  42. Data suggest that H-Ras inhibits TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through downregulation of surface death receptors DR4/DR5. PMID: 25026275
  43. Over-expression of TRAIL-R2 is associated with breast cancer. PMID: 25230899
  44. The results show that both TRAIL-R1 and TRAIL-R2 are highly expressed on human oligodendrocyte progenitors. PMID: 25845236
  45. Further analysis demonstrated that PARP inhibitor treatment results in activation of the FAS and TNFRSF10B (death receptor 5 (DR5)) promoters, increased Fas and DR5 mRNA, and elevated cell surface expression of these receptors in sensitized cells PMID: 24895135
  46. This study demonstrated lower apoptosis correlated with a deficiency of DR5 cell surface expression by CD4 T cells upon HIV-1 stimulation. PMID: 25110157
  47. Report RR5 up-regulation in alveolar epithelial cells from idiopathic pulmonary fibrosis patients. PMID: 24551275
  48. Primary EOC is associated with lower TRAIL-R2 and BCL2 expression levels, while metastatic EOC is associated with higher expression of these genes. PMID: 24190693
  49. Parthenolide triggers extrinsic apoptosis by up-regulating TNFRSF10B and intrinsic apoptosis through increasing the expression of PMAIP1. PMID: 24387758
  50. Cotreatment with MESC and an ERK inhibitor (PD98059) significantly increased the expression of DR5 to induce apoptosis...MESC may induce apoptosis via the ERK pathway and may be a potential anticancer drug candidate against human oral MEC. PMID: 24270523
  51. DR5 integrates opposing UPR signals to couple the endoplasmic reticulum stress and apoptotic cell fate. PMID: 24994655
  52. Low doses of triptolide sensitize cancer cells to TRAIL mediated death via death receptor 5. PMID: 24662747
  53. Human embryonic and induced pluripotent stem cells express TRAIL-1 and TRAIL-2 receptors and can be sensitized to TRAIL-induced apoptosis. PMID: 23806100
  54. As detected by western blot analysis and real-time RT-PCR, ibuprofen upregulated the expression of death receptor 5 (DR5), a TRAIL receptor. PMID: 24002210
  55. these results indicate that CAPE potentiated TRAIL-induced apoptosis in SK-Hep1 cells, through upregulation of TRAIL receptors(DR4 and DR5) via modulation of p38 and JNK signaling pathways. PMID: 23857473
  56. Data suggest that doxorubicin (DOX)-induced recruitment of death receptor 5 (DR5) to the cell surface impacts the enhanced apoptotic effect that can be longitudinally monitored by apoptosis imaging. PMID: 23908588
  57. Assessed if casticin induces caspase-mediated apoptosis via activation of mitochondrial pathway and upregulation of DR5 in human lung cancer cells. PMID: 23608376
  58. Nuclear TRAIL-R2 inhibits maturation of the microRNA let-7 in pancreatic cancer cell lines and increases their proliferation. Pancreatic tumor samples have increased levels of nuclear TRAIL-R2, which correlate with poor outcome of patients. PMID: 24120475
  59. CHOP-mediated DR5 upregulation and proteasome-mediated downregulation of c-FLIP. PMID: 23615398
  60. CBX enhanced TRAIL-induced apoptosis through upregulation of death receptor 5, blockade of GJ intercellular communication, and downregulation of connexin 43 PMID: 23428290
  61. Ack1 acts in a kinase-independent manner to promote TRAIL-R1/2 accumulation in lipid rafts. These findings identify Ack1 as an essential player in the spatial regulation of TRAIL-R1/2. PMID: 24085293
  62. TNFRSF10B polymorphisms and haplotypes are associated with increased risk of non-small cell lung cancer. PMID: 23839018
  63. vThe antiproliferative GSI-I/TRAIL synergism was stronger in ER-negative MDA-MB-231 breast cancer cells compared with ER-positive MCF-7 cells. In MDA-MB-231 cells, GSI-I treatment induced upregulation of DR4 and DR5 TRAIL receptors PMID: 23686163
  64. TRAIL-induced apoptosis in human renal cancer cells by upregulation of DR5 as well as downregulation of c-FLIP and Bcl-2. PMID: 22842544
  65. Deletion of TRAIL-R2 is relevant to the loss of 8p21.3 and plays an important role in the pathogenesis of multiple myeloma. PMID: 23423784
  66. DR5 upregulation in this case is mediated by C/EBP homology protein (CHOP), an important endoplasmic reticulum stress responsive protein. PMID: 23053497
  67. research may provide a backbone for understanding structural and functional insights of TNFRSF10B protein. The designed novel inhibitors and predicted interactions might serve to inhibit the disease PMID: 23724937
  68. Human cytomegalovirus UL141 binds to cellular TRAIL-R1 and TRAIL-R2 and protects virus infected cells from NK cell-mediated killing. PMID: 23498957
  69. Data indicate that isoflavone biochanin-A sensitized the TRAIL-resistant LNCaP cells through the inhibition of transcription factor NF-kappaB(p65) activity and increased the expression of the death receptor TRAIL-R2 (DR5). PMID: 21803611
  70. The fraction of pancreatic cancer samples with positive membrane staining for TRAIL-R1 and TRAIL-R2 was lower than that of cells from surrounding non-tumor tissues. PMID: 23460812
  71. Up-regulation of DR4 and DR5 overcomes TRAIL resistance in glioblastoma cells in vitro and in vivo. PMID: 22824792
  72. Upregulation of DR4 and DR5 and colocalization with Abeta at the cell membrane suggests their involvement as initiators of the apoptotic machinery PMID: 22695614
  73. Studies indicate that the anti-apoptotic protein c-FLIP is an important regulator of death receptor signaling, including TNFR1, Fas, DR4, and DR5. PMID: 23322903
  74. Loss of membrane TRAIL-R2 expression is associated with early stage colorectal cancer. PMID: 23284732
  75. pJNK2, CHOP, and DR5 are upregulated by gamma-tocopherol in breast cancer cell lines. PMID: 23065795
  76. BCR-ABL is critically involved in the leukemia-specific expression of DR4 and DR5 and in the susceptibility of Ph(+) leukemia to TRAIL-mediated anti-leukemic activity. PMID: 22665066
  77. Increased TRAIL-R2 expression on T cells in chronic hepatitis B. PMID: 23254287
  78. analysis of small-molecule activation of the TRAIL receptor DR5 in human cancer cells PMID: 23292651
  79. hDR5 reactive immune serum prevented growth of SUM159 TNBC cells in severe combined immune-deficient mice. PMID: 22419388
  80. Gene silencing of DR5 by short hairpin RNA reduced the apoptosis induced by combination treatment of mitomycin C and TRAIL in colon cancer cells. PMID: 22895172
  81. Plumbagin alone could markedly up-regulate DR5 mRNA and protein expression, and slightly increase DR4 mRNA and protein expression in A375 cells. PMID: 20714870
  82. these results identify the expression of MAGE-D2 suppresses TRAIL receptor 2 and protects againstas TRAIL-induced apoptosis PMID: 22791814
  83. Studies suggest that TNF-related apoptosis-inducing ligand (TRAIL) plays broader roles in regulating immune processes. PMID: 23091198
  84. DR5 is modulated by the ATF4-ATF3-CHOP axis in human NSCLC cells after Sirt1/2 inhibition or salermide treatment. PMID: 21801305
  85. Endometriosis is not associated with DR5 gene polymorphism. PMID: 22392486
  86. Data indicate taht decreased serum death receptor 5 (sDR5) is associated with high level of liver damage and inhibited HBV antigen expression. PMID: 22537456
  87. Data show that bufalin-induced down-regulation of Cbl-b contributed to the up-regulation of TRAIL Receptors DR4 and DR5. PMID: 22447040
  88. Vascular disruption and antitumor activity required DR5 expression on tumor ECs but not malignant cells. These results establish a therapeutic paradigm for proapoptotic receptor agonists as selective tumor vascular disruption agents PMID: 22789540
  89. Endoplasmic reticulum stress alters the cellular levels of different apoptosis-related proteins including a decline in the levels of FLIP and Mcl-1 and the up-regulation of TRAIL-R2. PMID: 22072062
  90. membrane DR5 expression leading to TRAIL-mediated apoptosis may represent one of the pathways responsible for eradication of over-activated CD4(+) T cells during immune responses. PMID: 22412938
  91. A new single-chain fragment variable (scFv) to TRAIL-R2 receptor produced as minibody (MB2.23) significantly increase the median survival time of lymphoma-bearing animals. PMID: 20714918
  92. Data show that a higher expression of FAS receptor, FAS ligand, TrailR1 and TrailR2 on T cells or blasts of acute myeloid leukemia (AML) patients is associated with a better prognosis. PMID: 22183068
  93. Ras induces DR5 expression through co-activation of ERK/RSK and JNK signaling pathways PMID: 22065586
  94. Findings suggest that the importin beta1-mediated nuclear localization of DR5 limits the DR5/TRAIL-induced cell death of human tumor cells and thus can be a novel target to improve cancer therapy with recombinant TRAIL and anti-DR5 antibodies. PMID: 22020938
  95. DR4 and DR5 have a capability to activate Nox1 by recruiting RFK, resulting in ROS-mediated apoptotic cell death in tumor cells. PMID: 22158615
  96. p53 and DR5 expression decreased progressively with colorectal caner stage, suggesting that these proteins are important markers of advanced tumor stages. PMID: 21805040
  97. Data show that TRAIL sensitive cancer cells have higher DR4 and DR5 expression on the cell surface. PMID: 21785270
  98. Alpha-fetoprotein interacted with RAR-beta and suppressed the expression of DR5 in hepatoma cells. PMID: 21059290
  99. lupulone-triggered enhanced expression of p38 plays a major role in the activation of p53 and of the TRAIL-death receptor apoptotic pathway in SW620 human colon cancer-derived metastatic cells PMID: 21519792
  100. Critical difference between DR4- and DR5-mediated apoptotic signaling modulation. PMID: 21272366

Show More

Hide All

Involvement in disease Squamous cell carcinoma of the head and neck (HNSCC)
Subcellular Location Membrane, Single-pass type I membrane protein
Tissue Specificity Widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines such as HeLaS3, K-562, HL-60, SW480, A-549 and G-361; highly expressed in heart, peripheral blood lymphocytes, liver, pancreas, spleen, thymus, prostate, ovary, uterus,
Database Links

HGNC: 11905

OMIM: 275355

KEGG: hsa:8795

STRING: 9606.ENSP00000276431

UniGene: Hs.521456

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1